MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

LY 303511

CAS No. : 154447-38-8

MCE 站：LY 303511

产品活性：LY303511 是 LY294002 的一种结构类似物，但 LY303511 不抑制 PI3K。LY303511 可增强 SHEP-1 神经母细胞瘤细胞的TRAIL 敏感性。LY303511 可逆地阻断 MIN6 胰岛瘤细胞中的 K⁺ 电流 (IC₅₀=64.6±9.1 μM)。

研究领域：Apoptosis  |  Membrane Transporter/Ion Channel

作用靶点：TNF Receptor  |  Potassium Channel

In Vitro: LY303511 is structurally identical to LY294002 except for a substitution of -O for -NH in the morpholine ring, and does not potently inhibit PI3K. Treatment of cells with LY303511 causes an increase in calcein spread similar to levels of LY294002. The ability of LY303511 to increase gap junctional intercellular communication (GJIC) does not occur concomitant with inhibition of phosphorylation of AKT as measured by immunoblotting. LY303511 enhances TRAIL sensitivity of SHEP-1 neuroblastoma cells via H₂O₂-MAPK activation and up-regulation of death receptors. SHEP-1 cells are exposed to varying concentrations of LY303511 (LY30), TRAIL, and a combination of the two (1 h preincubation with LY303511 followed by TRAIL for 4 hours). SHEP-1 cells are responsive to TRAIL (~10%, ~15%, and ~30% reduction in the surviving fraction at 25, 50, and 100 ng/mL, respectively); however, treatment with LY303511 (12.5, 25, or 50 μM) has no effect on cell viability. However, incubation of cells with LY303511 (25 μM) for 1 hour followed by 4 hours exposure to 50 ng/mL of TRAIL has a strong synergistic effect (~40% reduction in viable cells with LY303511+TRAIL versus ~15% with TRAIL alone). LY303511 is a negative control compound with respect to PI3K activity. In MIN6 insulinoma cells, Wortmannin (100 nM) has no effect on whole-cell outward K⁺ currents, but LY294002 and LY303511 reversibly block currents in a dose-dependent manner (IC₅₀=9.0±0.7 μM and 64.6±9.1 μM, respectively). Kv2.1 and Kv1.4 are highly expressed in beta-cells, and in Kv2.1-transfected tsA201 cells, 50 μM LY294002 and 100 μM LY303511 reversibly inhibit currents by 99% and 41%, respectively. LY303511 blocks currents with an IC₅₀ of 64.6±9.1 ?M, with a maximal inhibition of ~90% at 500 ?M (n≥5 cells at each concentration).

In Vivo: Intraperitoneal administration of vehicle or LY303511 (10 mg/kg/day) is performed when tumors reach a volume of ~150 mm³, at which time 35 mice have developed a tumor. After 21 days, >15% of the mice require euthanasia because of excessive tumor growth, and these data are censored due to unreliable estimates of average tumor volume. The administration of LY303511, 10 mg/kg/day, is sufficient to inhibit PC-3 tumor growth in vivo.

相关产品：Resatorvid  |  Nigericin sodium salt  |  BAPTA-AM  |  Shikonin  |  Fisetin  |  N-Formyl-Met-Leu-Phe  |  Rosuvastatin Calcium  |  SKF-96365 hydrochloride  |  Glibenclamide  |  SCH-23390 hydrochloride  |  Adalimumab  |  R-7050  |  Tetrandrine  |  Amiodarone hydrochloride  |  QNZ  |  TRAM-34  |  Ifenprodil tartrate  |  Infliximab  |  Minoxidil  |  Diazoxide  |  20(S)-Ginsenoside Rg3  |  Senicapoc  |  Tannic acid  |  DCPIB  |  Astemizole  |  Ketanserin  |  Quinine  |  E-4031  |  Terfenadine  |  Hydrochlorothiazide

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。